| Literature DB >> 33748460 |
Khaled Alkethiri1, Tariq Almtroudi1, Abdullah Bin Jurays1, Faisal Abanumay1, Mohammed Aldammas1, Meshaal AlKhodheer1, Muhammad Iqbal2, Syed Shahid Habib2, Shahid Bashir3.
Abstract
BACKGROUND: Type 2 diabetes mellitus (T2DM) has been associated with impairment of cognitive functions. Since the majority of patients with diabetes in the Saudi population are between the ages of 40 and 69 years, it is crucial to ascertain whether the control of blood glucose level negatively correlates with the level of cognitive function scores similar to the way it correlates in those who are not controlling their blood glucose level with medications. AIMS: To assess cognitive functions in patients with T2DM and examine the effect of glycemic control on cognitive functions impairment in Saudi adults with T2DM. METHODS AND MATERIAL: Seventy-nine patients with T2DM underwent cognitive assessment testing using the Cambridge neuropsychological test automated battery (CANTAB), Mini-Mental State Examination (MMSE), and Fatigue severity scale. Their cognitive function scores were then correlated with their blood glucose levels, duration of diabetes, and levels of education. Poor glycemic control was defined as glycated hemoglobin levels more than 7.5. We excluded patients with depression or neurocognitive disorders as well as those over 75 years of age.Entities:
Keywords: CANTAB; Cognitive functions; Cognitive impairment; Duration of diabetes; Glycosylated hemoglobin; Type 2 diabetes mellitus
Year: 2021 PMID: 33748460 PMCID: PMC7969332 DOI: 10.1016/j.heliyon.2021.e06358
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Demographic characteristics of all type 2 Diabetes Mellitus (T2DM) patients.
| Variables | All subjects | Good Glycemic Control n = 36 | Poor Glycemic Control n = 43 | P value |
|---|---|---|---|---|
| M/F | 70/9 | 31/5 | 39/4 | |
| Age (Range) | 57.25 ± 9.80 (35–75) | 55.46 ± 10.81 | 58.13 ± 9.05 | 0.249 |
| Duration of DM (years) | 13.18 ± 8.59 | 10.90 ± 9.05 | 14.82 ± 8.15 | 0.080 |
| Hypertension | 24 (30.3%) | 11 (13.9%) | 13 (16.4%) | 0.382 |
| Renal Dysfunction | 10 (12.6%) | 4 (5%) | 6 (7.5%) | 0.537 |
| Ischemic Heart Disease | 11 (13.9%) | 5 (6%) | 6 (7.5%) | 0.524 |
| Peripheral Vascular Disease | 14 (17.7%) | 7 (8.8%) | 7 (8.8%) | 0.495 |
| Retinopathy | 9 (11.3%) | 4 (5%) | 5 (6%) | 0.382 |
values are compared by Chi Square test.
Comparison of demographic characteristics and biochemical profile of study subjects between controlled and uncontrolled type 2 Diabetes Mellitus (T2DM) patients.
| Good Glycemic Control n = 36 | Poor Glycemic Control n = 43 | P value | |
|---|---|---|---|
| M/F | 31/5 | 39/4 | |
| Duration of DM (years) | 12.04 ± 8.07 | 15.02 ± 9.23 | 0.201 |
| WBC X 109/L | 6.35 ± 4.46 | 5.06 ± 3.98 | 0.320 |
| HGB g/L | 102.04 ± 65.80 | 107.10 ± 62.70 | 0.819 |
| MCV μm3 | 66.14 ± 38.21 | 57.19 ± 41.77 | 0.292 |
| AST U/L | 8.68 ± 8.61 | 9.41 ± 10.07 | 0.869 |
| CREATININE μmol/L | 73.11 ± 154.11 | 42.12 ± 44.94 | 0.441 |
| GLUCOSE mmol/L | 4.94 ± 4.244 | 5.68 ± 6.05 | 0.593 |
| Gamma GT (IU)/L | 34.23 ± 40.28 | 24.51 ± 40.19 | 0.096 |
| HbA1c % | 6.32 ± 1.75 | 9.10 ± 1.45 | 0.001 |
| CHOLESTEROL mmol/L | 2.21 ± 2.33 | 2.90 ± 2.41 | 0.213 |
| HDL mmol/L | 0.54 ± 0.56 | 0.66 ± 0.56 | 0.356 |
| LDL mmol/L | 1.30 ± 1.53 | 1.53 ± 1.46 | 0.510 |
| Triglycerides mmol/L | 0.81 ± 0.91 | 1.64 ± 2.80 | 0.045 |
| Duration of DM (in years) | 10.91 ± 9.06 | 14.83 ± 8.15 | 0.084 |
Data is expressed as Mean ± SD, Differences were studied by Student's t test.
Comparison of cognitive function by Cambridge Neuropsychological Test Automated Battery test variables between controlled and uncontrolled type 2 Diabetes Mellitus (T2DM) patients.
| Good Glycemic Control n = 36 | Poor Glycemic Control n = 43 | P value | |
|---|---|---|---|
| AST Total Latency | 730.53 ± 291.19 | 938.21 ± 293.76 | 0.003 |
| AST congruent | 692.55 ± 286.80 | 912.71 ± 305.14 | 0.002 |
| AST incongruent | 777.33 ± 295.77 | 990.45 ± 298.69 | 0.003 |
| AST blocks3 | 672.17 ± 279.80 | 876.92 ± 307.40 | 0.004 |
| AST7 | 836.23 ± 344.84 | 1050.91 ± 304.50 | 0.006 |
| AST Percent | 50.66 ± 34.54 | 59.51 ± 53.41 | 0.416 |
| IED Total errors | 7.41 ± 1.50 | 8.09 ± 1.06 | 0.023 |
| IED Stages completed | 4.44 ± 1.98 | 4.58 ± 1.43 | 0.716 |
| SSP | 1.81 ± 0.69 | 1.76 ± 0.77 | 0.782 |
Data is expressed as Mean ± SD, Differences were studied by Student's t test.
Mini-mental State Examination (MMSE) and Fatigue Severity Scale (FSS) results between controlled and uncontrolled type 2 Diabetes Mellitus T2DM patients.
| Good Glycemic Control | Poor Glycemic Control | P value | |
|---|---|---|---|
| MMSE | Mean: 26.05 ± 5.74 | Mean:26.08 ± 4.34 | .336 |
| Fatigue scale mean | Mean:33.67 ± 16.99 | Mean:38.64 ± 14.784 | .167 |
Data is expressed as Mean ± SD, Differences were studied by Student's t test.
Figure 1Pearson's correlation between duration of type 2 Diabetes Mellitus (T2DM) and AST Latency.
Figure 2Pearson's correlation between duration of type 2 Diabetes Mellitus (T2DM) and AST Congruent Latency.
Figure 3Pearson's correlation between duration of type 2 Diabetes Mellitus (T2DM) and AST Incongruent Latency.